K Pharma (4896) · PolicyRestated
Policy to use R&D progress in the development pipeline as a performance indicator for evaluating management objectives
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Making Research and Development Progress an Evaluation Metric for Management GoalsA theme 9 companies write about · 0 as a headwind · 7 as a tailwind
The whole theme swung hardest in 2025: 2 of 8 companies on the "Worse" side.
3 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「We use the progress of research and development in each development pipeline of the iPS drug discovery and regenerative medicine businesses as a metric for assessing the achievement of management objectives.」
Before recurring revenue is generated, the company maintains its policy of using research and development progress in each pipeline as a management-performance metric. - FY2024First statedAnnual report
「We use the progress of research and development in each development pipeline of the iPS drug discovery and regenerative medicine businesses as a metric for assessing the achievement of management objectives.」
Before recurring revenue is generated, the company first explicitly stated that research and development progress in each pipeline of both businesses would be used to assess achievement of management objectives.